With decade of service experience in the field of structural biology and advanced computational

drug design platform, Creative Biostructure now provides MagHelix™ Library Design and

Preparation service that helps step forward its customers’ critical hit screening with reduced

timing and escalated “hit rate”.

The process of identifying molecules that may become medications from a vast number of

compound libraries is known as hit identification. As a result, compound libraries are critical

tools for drug discovery. With the identification of several disease-related targets and active

compounds, various drug screening technologies have raised the bar for the quality, amount,

and variety of compound libraries. To a certain extent, the quality of the compound library

impacts the speed and quality of small molecule drug development.

With compound library construction expertise and resourceful preassembled libraries covering

spotlight research subjects, Creative Biostructure provides the following custom-designed

libraries including but are not limited to:

Compound libraries for high-throughput screening (HTS)

Creative Biostructure's high-throughput equipment enables the screening of corresponding

compound libraries using a variety of detection methods, including optical, fluorescence,

radioactive detection technology, crystallography, and the multi-functional microplate detection

system.

Compound libraries for high-content screening (HCS)

Creative Biostructure's HCS equipment includes a high-resolution automated fluorescent

image acquisition system, image analysis and processing software, and a data management

system.

Screening libraries for in silico virtual screening

Creative Biostructure has a comprehensive computer-aided drug design (CADD) platform,

which enables us to offer custom in silico virtual screening services.

Fragment Libraries for fragment-based screening (FBS)

Creative Biostructure delivers FBS solutions for companies with hit identification needs, which

involve multiple biophysical approaches to detect the specific binding fragments, by using an

innovative fragment-based drug design (FBDD) platform.

“It is worth mentioning that, for each screening project, Screening Library Customization

Services are delivered to target the most potent compounds according to specific project goals.

Meanwhile, our screening team reviews hits from a biological/medicinal chemistry point of view

in order to ensure drug-like profiles with every drug discovery pipeline for biotechnology and pharmaceutical companies.” Commented Joanna, the chief marketing staff at Creative

Biostructure.

To know more detailed information, please visit https://drug-discovery.creative

biostructure.com/maghelix-library-design-and-preparation-p2